SCHEMBL30298632

SCHEMBL30298632

COc1ccc(C(=O)c2scnc2N)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.54
RAB9A P51151 3/20 0.54
MEN1 O00255 6/20 0.52
KMT2A Q03164 6/20 0.52
MAPT P10636 4/20 0.49
CDK5 Q00535 3/20 0.49
CDK5R1 Q15078 3/20 0.49
LMNA P02545 2/20 0.49
CA2 P00918 3/20 0.49
RXFP1 Q9HBX9 2/20 0.47
MAPK1 P28482 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
HPGD P15428 1/20 0.47
CA1 P00915 2/20 0.47
PARP1 P09874 1/20 0.47
PARP10 Q53GL7 1/20 0.47
PARP2 Q9UGN5 1/20 0.47
PARP4 Q9UKK3 1/20 0.47
CCNA2 P20248 1/20 0.47
CDK2 P24941 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8634199 0.83 KDM4E (0.51) NPC1RAB9AMEN1KMT2AMAPT
SCHEMBL30298642 0.82 KMT2A (0.43) NPC1RAB9AMEN1KMT2AMAPT
SCHEMBL30406419 0.80 CCNA2 (0.49) NPC1RAB9AMEN1KMT2AMAPT
SCHEMBL30298597 0.79 SRD5A2 (0.58) RAB9AMAPTLMNAPARP10GAA
SCHEMBL30298645 0.79 KMT2A (0.44) MEN1KMT2ACDK5CDK5R1LMNA
SCHEMBL13638606 0.75 MEN1 (0.67) NPC1RAB9AMEN1KMT2AMAPT
SCHEMBL9418310 0.73 RXFP1 (0.79) NPC1RAB9AMEN1KMT2AMAPT
SCHEMBL51509 0.73 RXFP1 (0.79) NPC1RAB9AMEN1KMT2AMAPT
SCHEMBL1872764 0.72 MAPK1 (0.67) NPC1RAB9AMEN1KMT2AMAPT
SCHEMBL5141691 0.72 MAPK1 (0.67) NPC1RAB9AMEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11964953-B2 Substituted aminothiazoles as DGKzeta inhibitors for immune activation BAYER AKTIENGESELLSCHAFT (DE) 2024-04-23 US disclosed
US-20230167078-A1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION BAYER AKTIENGESELLSCHAFT (DE) 2023-06-01 US disclosed
US-20230139936-A1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION BAYER AKTIENGESELLSCHAFT (DE) 2023-05-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230139936-A1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION DGKZ, DGKA, DGKG NPC1 3336/4885RAB9A 951/4885MEN1 4344/4885
US-20230167078-A1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION DGKZ, DGKA, DGKG NPC1 3336/4885RAB9A 951/4885MEN1 4344/4885
US-11964953-B2 Substituted aminothiazoles as DGKzeta inhibitors for immune activation DGKZ, DGKA, DGKG NPC1 3336/4885RAB9A 951/4885MEN1 4344/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.